- Home
- SGC vs CRDF Comparison
SGC vs CRDF Comparison
Compare SGC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGC | CRDF |
|---|---|---|
| Founded | 1920 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SGC | CRDF |
|---|---|---|
| Price | $9.85 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $17.33 | $10.63 |
| AVG Volume (30 Days) | 64.3K | ★ 914.5K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $565,017,000.00 | $501,000.00 |
| Revenue This Year | $1.07 | N/A |
| Revenue Next Year | $3.03 | N/A |
| P/E Ratio | $27.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.30 | $1.90 |
| 52 Week High | $16.91 | $5.00 |
Technical Indicators
Market Signals| Indicator | SGC | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 65.93 |
| Support Level | $9.90 | $2.32 |
| Resistance Level | $10.28 | $2.59 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 16.56 | 94.69 |
Price Performance
Historical ComparisonAbout SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.